Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin.
DOI:
https://doi.org/10.26641/2307-0404.2015.2.45652Keywords:
dyslipidemia, cardiometabolic risk, statins, pitavastatinAbstract
. The review is devoted to the most important aspects of primary mixed dyslipidemia treatment in patients at high risk with concomitant metabolic comorbidities. Evidences for novel modern approaches regarding primary prevention of cardiovascular events among dyslipidemic patients are considered. The potential role of lipid-lowering treatment with statins and their role in reducing the cardiovascular risk are discussed. Information about modern methods of minimization of residual cardiovascular risk using a combined lipid-lowering strategies and new representatives of the statins are provided.Ithasbeendiscussedvariousstrategiesofstatinadministeringtopatientswithdyslipidemiaof different agewith exiting comorbidities, such as diabetes mellitus, obesity, metabolic syndrome. Objective findingsand treatment approaches obtainedfromthe patientwithobesity, metabolic syndrome, and asymptomatic atherosclerosis are provided. The role of pitavastatin in primary prevention program of cardiovascular events is discussed.
References
Anderson TJ, Grégoire J, Hegele RA. 2012 up¬date of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Car¬diol. 2013;29(2):151-67. 2. Stone NJ, Robinson JG, Lichtenstein AH. 2013 ACC/AHA Cholesterol Guideline Panel. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cho¬lesterol guideline. Ann. Intern. Med. 2014;160(5):339-43. 3. da Silva PM. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. Am J Car¬diovasc Drugs. 2011;11(2):93-107. 4. Chapman MJ. Pitavastatin: novel effects on lipid parameters. Atheroscler Suppl. 2011;12(3):277-84. 5. Otvos JD, Mora S, Shalaurova I. Clinical im¬plications of discordance between low-density lipoprotein cholesterol and particle number. J. Clin. Lipidol. 2011;5(2):105-13. 6. Catapano A, Reiner Z, de Backer G. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force on the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis; 2011. doi:10.1016/j.atherosclerosis.2011.06.012 [Epub ahead of print]. 7. Reiner Z, Catapano АL, De Backer G. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011;32:1769-818. 8. Chapman MJ, Ginsberg HN, Amarenco P. Euro¬pean Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipo¬protein cholesterol in patients at high risk of cardio¬vascular disease: evidence and guidance for management. Eur. Heart. J. 2011;32:1345-61. 9. Barter P, Gotto AM, LaRosa JC. HDL choles¬terol, very low levels of LDL cholesterol, and cardio¬vascular events. N. Engl. J. Med. 2007;357:1301-10. 10. Hibi K, Kimura T, Kimura K. JAPAN-ACS In¬vestigators. Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial. Atherosclerosis. 2011;219(2):743-9. 11. Takashima H, Ozaki Y, Morimoto T. JAPAN-ACS Investigators. Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN- ACS subanalysis study. Circ J. 2012;76(12):2840-7. 12. Hiro T, Kimura T, Morimoto T. JAPAN-ACS Investigators. Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome - serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). Circ. J. 2010;74(6):1165-74. 13. Arai H, Hiro T, Kimura T. JAPAN-ACS In¬vesti¬gators. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome - sub-analysis of JAPAN-ACS study. J. Atheroscler. Thromb. 2010;17(10):1096-107. 14. Fukushima Y, Daida H, Morimoto T. JAPAN-ACS Investigators. Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol. 2013;12(5). 15. Yamashita S, Tsubakio-Yamamoto K. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J. Atheroscler Thromb. 2010;17(5):436-51. 16. Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin. Pharmacother. 2010;11(5):817-28. 17. Qureshi N, Humphries SE, Seed M. NICE Guideline Development Group. Identification and ma¬na¬ge¬ment of familial hypercholesterolaemia: what does it mean to primary care? Br. J. Gen. Pract. 2009;59(567):773-6. 18. Jaques H. NICE guideline on lipid modification. Eur. Heart. J. 2013;34(7):481-2. 19. Preiss D, Seshasai SR, Welsh P. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556-64. 20. Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipo¬protein management in patients with cardiometabolic residual risk. Atherosclerosis. 2010;213(1):1-7. 21. Saito Y. Pitavastatin: an overview. Atheroscler Suppl. 2011;12(3):271-6. 22. Mannu GS, Zaman MJ, Gupta A. Update on guidelines for management of hypercholesterolemia. Expert Rev. Cardiovasc. Ther. 2012;10(10):1239-49.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Medical Perspectives
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
